Cargando…

A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients

BACKGROUND: The nomograms used for prostate cancer risk assessment in Western countries are not directly applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them developing this disease. METHODS: A total of 1104 patients who had undergone trans-rectal ult...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuan, Cheng, Gong, Liu, Bianjiang, Shao, Pengfei, Qin, Chao, Li, Jie, Hua, Lixin, Yin, Changjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893548/
https://www.ncbi.nlm.nih.gov/pubmed/24410803
http://dx.doi.org/10.1186/1471-2490-14-8
_version_ 1782299713062567936
author Huang, Yuan
Cheng, Gong
Liu, Bianjiang
Shao, Pengfei
Qin, Chao
Li, Jie
Hua, Lixin
Yin, Changjun
author_facet Huang, Yuan
Cheng, Gong
Liu, Bianjiang
Shao, Pengfei
Qin, Chao
Li, Jie
Hua, Lixin
Yin, Changjun
author_sort Huang, Yuan
collection PubMed
description BACKGROUND: The nomograms used for prostate cancer risk assessment in Western countries are not directly applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them developing this disease. METHODS: A total of 1104 patients who had undergone trans-rectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy were retrospectively evaluated in the first stage of the study. Age, prostate-specific antigen (PSA), the free/total PSA ratio (f/t), digital rectal examination (DRE) findings, the presence of a hypoechoic mass revealed using ultrasound, ultrasonic detection of microcalcifications, prostate volume (PV) and PSA density were considered as predictive factors. Multiple logistic regression analysis involving a backward elimination selection procedure was used to select independent predictors. We compared positive rates regarding 6-core and 12-core biopsy schemes at different risk levels. In the second stage of the study, 238 cases were evaluated using our nomogram. In higher risk patients, we employed a 6 + 1 core biopsy. Positive rates in the first and second stages of the study were compared. RESULTS: Age, the baseline median natural logarithm of PSA (Ln[PSA]), Ln(PV), f/t, rate of abnormal DRE findings and rate of hypoechoic masses detected using TRUS were the factors that were finally submitted into our nomogram. A significantly greater area under the receiver-operating characteristic curve was obtained for the nomogram than for PSA level alone (0.853 vs. 0.761). A cancer probability cutoff value of 0.5 suggested no significant difference between the 6-core and 12-core biopsy schemes at higher risk levels. In the second stage of the study we verified that in patients with a cancer probability cutoff value >0.5, a 6 + 1-core biopsy could be used without a reduction in the positive detection rate, and significantly reducing the number of biopsy cores required. CONCLUSIONS: A nomogram based on data from Chinese males was developed to predict the positive detection rate, ratio of positive cores and Gleason score at each risk level. According to this nomogram, a reasonable biopsy strategy could be constituted to reduce the number of biopsy cores required in subjects at high risk.
format Online
Article
Text
id pubmed-3893548
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38935482014-01-27 A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients Huang, Yuan Cheng, Gong Liu, Bianjiang Shao, Pengfei Qin, Chao Li, Jie Hua, Lixin Yin, Changjun BMC Urol Research Article BACKGROUND: The nomograms used for prostate cancer risk assessment in Western countries are not directly applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them developing this disease. METHODS: A total of 1104 patients who had undergone trans-rectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy were retrospectively evaluated in the first stage of the study. Age, prostate-specific antigen (PSA), the free/total PSA ratio (f/t), digital rectal examination (DRE) findings, the presence of a hypoechoic mass revealed using ultrasound, ultrasonic detection of microcalcifications, prostate volume (PV) and PSA density were considered as predictive factors. Multiple logistic regression analysis involving a backward elimination selection procedure was used to select independent predictors. We compared positive rates regarding 6-core and 12-core biopsy schemes at different risk levels. In the second stage of the study, 238 cases were evaluated using our nomogram. In higher risk patients, we employed a 6 + 1 core biopsy. Positive rates in the first and second stages of the study were compared. RESULTS: Age, the baseline median natural logarithm of PSA (Ln[PSA]), Ln(PV), f/t, rate of abnormal DRE findings and rate of hypoechoic masses detected using TRUS were the factors that were finally submitted into our nomogram. A significantly greater area under the receiver-operating characteristic curve was obtained for the nomogram than for PSA level alone (0.853 vs. 0.761). A cancer probability cutoff value of 0.5 suggested no significant difference between the 6-core and 12-core biopsy schemes at higher risk levels. In the second stage of the study we verified that in patients with a cancer probability cutoff value >0.5, a 6 + 1-core biopsy could be used without a reduction in the positive detection rate, and significantly reducing the number of biopsy cores required. CONCLUSIONS: A nomogram based on data from Chinese males was developed to predict the positive detection rate, ratio of positive cores and Gleason score at each risk level. According to this nomogram, a reasonable biopsy strategy could be constituted to reduce the number of biopsy cores required in subjects at high risk. BioMed Central 2014-01-11 /pmc/articles/PMC3893548/ /pubmed/24410803 http://dx.doi.org/10.1186/1471-2490-14-8 Text en Copyright © 2014 Huang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Huang, Yuan
Cheng, Gong
Liu, Bianjiang
Shao, Pengfei
Qin, Chao
Li, Jie
Hua, Lixin
Yin, Changjun
A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title_full A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title_fullStr A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title_full_unstemmed A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title_short A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
title_sort prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893548/
https://www.ncbi.nlm.nih.gov/pubmed/24410803
http://dx.doi.org/10.1186/1471-2490-14-8
work_keys_str_mv AT huangyuan aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT chenggong aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT liubianjiang aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT shaopengfei aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT qinchao aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT lijie aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT hualixin aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT yinchangjun aprostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT huangyuan prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT chenggong prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT liubianjiang prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT shaopengfei prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT qinchao prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT lijie prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT hualixin prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients
AT yinchangjun prostatebiopsystrategybasedonanewclinicalnomogramreducesthenumberofbiopsycoresrequiredinhighriskpatients